Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis

H. Sogabe, M. Nangaku, Y. Ishibashi, T. Wada, T. Fujita, X. Sun, T. Miwa, Michael P. Madaio, W. C. Song

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

To prevent complement-mediated autologous tissue damage, host cells express a number of membrane-bound complement inhibitors. Decay-accelerating factor (DAF, CD55) is a GPI-linked membrane complement regulator that is widely expressed in mammalian tissues including the kidney. DAF inhibits the C3 convertase of both the classical and alternative pathways. Although DAF deficiency contributes to the human hematological syndrome paroxysmal nocturnal hemoglobinuria, the relevance of DAF in autoimmune tissue damage such as immune glomerulonephritis remains to be determined. In this study, we have investigated the susceptibility of knockout mice that are deficient in GPI-anchored DAF to nephrotoxic serum nephritis. Injection of a subnephritogenic dose of rabbit anti-mouse glomerular basement membrane serum induced glomerular disease in DAF knockout mice but not in wild-type controls. When examined at 8 days after anti-glomerular basement membrane treatment, DAF knockout mice had a much higher percentage of diseased glomeruli than wild-type mice (68.8 ± 25.0 vs 10.0 ± 3.5%; p < 0.01). Morphologically, DAF knockout mice displayed increased glomerular volume (516 ± 68 vs 325 ± 18 × 103 μm3 per glomerulus; p < 0.0001) and cellularity (47.1 ± 8.9 vs 32.0 ± 3.1 cells per glomerulus; p < 0.01). Although the blood urea nitrogen level showed no difference between the two groups, proteinuria was observed in the knockout mice but not in the wild-type mice (1.4 ± 0.7 vs 0.02 ± 0.01 mg/24 h albumin excretion). The morphological and functional abnormalities in the knockout mouse kidney were associated with evidence of increased complement activation in the glomeruli. These results support the conclusion that membrane C3 convertase inhibitors like DAF play a protective role in complement-mediated immune glomerular damage in vivo.

Original languageEnglish (US)
Pages (from-to)2791-2797
Number of pages7
JournalJournal of Immunology
Volume167
Issue number5
DOIs
StatePublished - Sep 1 2001

Fingerprint

CD55 Antigens
Glomerular Basement Membrane
Glomerulonephritis
Knockout Mice
Complement Inactivating Agents
Membranes
Classical Pathway Complement C3 Convertase
Alternative Pathway Complement C3 Convertase
Complement C3-C5 Convertases
Paroxysmal Hemoglobinuria
Kidney
Nephritis
Complement Activation
Blood Urea Nitrogen
Serum
Proteinuria
Albumins
Rabbits
Injections

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis. / Sogabe, H.; Nangaku, M.; Ishibashi, Y.; Wada, T.; Fujita, T.; Sun, X.; Miwa, T.; Madaio, Michael P.; Song, W. C.

In: Journal of Immunology, Vol. 167, No. 5, 01.09.2001, p. 2791-2797.

Research output: Contribution to journalArticle

Sogabe, H, Nangaku, M, Ishibashi, Y, Wada, T, Fujita, T, Sun, X, Miwa, T, Madaio, MP & Song, WC 2001, 'Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis', Journal of Immunology, vol. 167, no. 5, pp. 2791-2797. https://doi.org/10.4049/jimmunol.167.5.2791
Sogabe, H. ; Nangaku, M. ; Ishibashi, Y. ; Wada, T. ; Fujita, T. ; Sun, X. ; Miwa, T. ; Madaio, Michael P. ; Song, W. C. / Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis. In: Journal of Immunology. 2001 ; Vol. 167, No. 5. pp. 2791-2797.
@article{6e7cd89862f744d4ac3ad911e7f40382,
title = "Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis",
abstract = "To prevent complement-mediated autologous tissue damage, host cells express a number of membrane-bound complement inhibitors. Decay-accelerating factor (DAF, CD55) is a GPI-linked membrane complement regulator that is widely expressed in mammalian tissues including the kidney. DAF inhibits the C3 convertase of both the classical and alternative pathways. Although DAF deficiency contributes to the human hematological syndrome paroxysmal nocturnal hemoglobinuria, the relevance of DAF in autoimmune tissue damage such as immune glomerulonephritis remains to be determined. In this study, we have investigated the susceptibility of knockout mice that are deficient in GPI-anchored DAF to nephrotoxic serum nephritis. Injection of a subnephritogenic dose of rabbit anti-mouse glomerular basement membrane serum induced glomerular disease in DAF knockout mice but not in wild-type controls. When examined at 8 days after anti-glomerular basement membrane treatment, DAF knockout mice had a much higher percentage of diseased glomeruli than wild-type mice (68.8 ± 25.0 vs 10.0 ± 3.5{\%}; p < 0.01). Morphologically, DAF knockout mice displayed increased glomerular volume (516 ± 68 vs 325 ± 18 × 103 μm3 per glomerulus; p < 0.0001) and cellularity (47.1 ± 8.9 vs 32.0 ± 3.1 cells per glomerulus; p < 0.01). Although the blood urea nitrogen level showed no difference between the two groups, proteinuria was observed in the knockout mice but not in the wild-type mice (1.4 ± 0.7 vs 0.02 ± 0.01 mg/24 h albumin excretion). The morphological and functional abnormalities in the knockout mouse kidney were associated with evidence of increased complement activation in the glomeruli. These results support the conclusion that membrane C3 convertase inhibitors like DAF play a protective role in complement-mediated immune glomerular damage in vivo.",
author = "H. Sogabe and M. Nangaku and Y. Ishibashi and T. Wada and T. Fujita and X. Sun and T. Miwa and Madaio, {Michael P.} and Song, {W. C.}",
year = "2001",
month = "9",
day = "1",
doi = "10.4049/jimmunol.167.5.2791",
language = "English (US)",
volume = "167",
pages = "2791--2797",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "5",

}

TY - JOUR

T1 - Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis

AU - Sogabe, H.

AU - Nangaku, M.

AU - Ishibashi, Y.

AU - Wada, T.

AU - Fujita, T.

AU - Sun, X.

AU - Miwa, T.

AU - Madaio, Michael P.

AU - Song, W. C.

PY - 2001/9/1

Y1 - 2001/9/1

N2 - To prevent complement-mediated autologous tissue damage, host cells express a number of membrane-bound complement inhibitors. Decay-accelerating factor (DAF, CD55) is a GPI-linked membrane complement regulator that is widely expressed in mammalian tissues including the kidney. DAF inhibits the C3 convertase of both the classical and alternative pathways. Although DAF deficiency contributes to the human hematological syndrome paroxysmal nocturnal hemoglobinuria, the relevance of DAF in autoimmune tissue damage such as immune glomerulonephritis remains to be determined. In this study, we have investigated the susceptibility of knockout mice that are deficient in GPI-anchored DAF to nephrotoxic serum nephritis. Injection of a subnephritogenic dose of rabbit anti-mouse glomerular basement membrane serum induced glomerular disease in DAF knockout mice but not in wild-type controls. When examined at 8 days after anti-glomerular basement membrane treatment, DAF knockout mice had a much higher percentage of diseased glomeruli than wild-type mice (68.8 ± 25.0 vs 10.0 ± 3.5%; p < 0.01). Morphologically, DAF knockout mice displayed increased glomerular volume (516 ± 68 vs 325 ± 18 × 103 μm3 per glomerulus; p < 0.0001) and cellularity (47.1 ± 8.9 vs 32.0 ± 3.1 cells per glomerulus; p < 0.01). Although the blood urea nitrogen level showed no difference between the two groups, proteinuria was observed in the knockout mice but not in the wild-type mice (1.4 ± 0.7 vs 0.02 ± 0.01 mg/24 h albumin excretion). The morphological and functional abnormalities in the knockout mouse kidney were associated with evidence of increased complement activation in the glomeruli. These results support the conclusion that membrane C3 convertase inhibitors like DAF play a protective role in complement-mediated immune glomerular damage in vivo.

AB - To prevent complement-mediated autologous tissue damage, host cells express a number of membrane-bound complement inhibitors. Decay-accelerating factor (DAF, CD55) is a GPI-linked membrane complement regulator that is widely expressed in mammalian tissues including the kidney. DAF inhibits the C3 convertase of both the classical and alternative pathways. Although DAF deficiency contributes to the human hematological syndrome paroxysmal nocturnal hemoglobinuria, the relevance of DAF in autoimmune tissue damage such as immune glomerulonephritis remains to be determined. In this study, we have investigated the susceptibility of knockout mice that are deficient in GPI-anchored DAF to nephrotoxic serum nephritis. Injection of a subnephritogenic dose of rabbit anti-mouse glomerular basement membrane serum induced glomerular disease in DAF knockout mice but not in wild-type controls. When examined at 8 days after anti-glomerular basement membrane treatment, DAF knockout mice had a much higher percentage of diseased glomeruli than wild-type mice (68.8 ± 25.0 vs 10.0 ± 3.5%; p < 0.01). Morphologically, DAF knockout mice displayed increased glomerular volume (516 ± 68 vs 325 ± 18 × 103 μm3 per glomerulus; p < 0.0001) and cellularity (47.1 ± 8.9 vs 32.0 ± 3.1 cells per glomerulus; p < 0.01). Although the blood urea nitrogen level showed no difference between the two groups, proteinuria was observed in the knockout mice but not in the wild-type mice (1.4 ± 0.7 vs 0.02 ± 0.01 mg/24 h albumin excretion). The morphological and functional abnormalities in the knockout mouse kidney were associated with evidence of increased complement activation in the glomeruli. These results support the conclusion that membrane C3 convertase inhibitors like DAF play a protective role in complement-mediated immune glomerular damage in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0035451680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035451680&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.167.5.2791

DO - 10.4049/jimmunol.167.5.2791

M3 - Article

C2 - 11509624

AN - SCOPUS:0035451680

VL - 167

SP - 2791

EP - 2797

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 5

ER -